FIELD: medicine; pharmacology.
SUBSTANCE: formulation contains N-carbamoyl-methyl-4-phenyl-2-pyrrolidone as active principle and solubilising neutral organic component selected from the group that comprises diamide of carbonic acid, and/or monosaccharides, and/or disaccharides, and/or polyatomic spirits or their homogeneous mixture, with mass relation of N-carbamoyl-methyl-4-phenyl-2-pyrrolidone and specified solubilising component 1:(0.15-5). Method for preparation of pharmaceutical formulation consists in the fact that formulation components are simultaneously and separately evaporated in depressurised gas medium, and produced vapors are cocondensated on the surface of sedimentation cooled down to negative temperature. The second version of method for preparation of pharmaceutical formulation consists in the fact that formulation components are previously dissolved in water, solution is frozen to the temperature of not higher than - 60°C, then frozen solution is sublimated in depressurised gas medium, and adsorbed water remainder is removed in prepared pharmaceutical formulation. Invention provides for preparation of water-soluble pharmaceutical formulation on the basis of N-carbamoyl-methyl-4-phenyl-2-pyrrolidone.
EFFECT: formulation is suitable for preparation of injection, suspension dosage forms.
3 cl, 8 dwg, 4 ex
